NVS - יחס חוב להיוון בספרים Novartis Inc.

Novartis AG (NVS) is balancing the risks of patent expirations with the implementation of breakthrough treatments, relying on the acquisition of promising biotech startups. The financing structure, specifically debt-to-book capitalization, reflects capital dynamics where the indicator has reached the level of 1.11. Business stability is maintained through strategic outsourcing of production and clinical trials, which optimizes costs and strengthens supply chains.

The investor utilizes a comparative asset analysis to determine the degree of Novartis AG (NVS) dependence on debt relative to its market value. This metric measures financial leverage, where a decrease in the indicator minimizes default risk, while an increase may suggest borrowing to fund the outsourcing of research and production, as confirmed by the debt-to-book capitalization ratio assessment.